LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lipocine Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.53−0.03 (-1.92%)
Close on Oct 19, 2026
- Market cap
- $12.57M
- P/E (TTM)
- –
- Dividend yield
- –
Lipocine Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| License [Member] | $1.50M | $10.90M | $109.99K | $500.00K | $11.00M | 75.9% | -86.2% |
| Royalty [Member] | $476.68K | $298.14K | – | – | – | 24.1% | +59.9% |
| Sales Based Royalties [Member] | – | – | – | – | $54.99K | – | – |
| Minimum Guaranteed Royalties [Member] | – | – | -$2.96M | – | $4.05M | – | – |
| Materials [Member] | – | – | – | – | $1.04M | – | – |
By region
From the segment and revenue-disaggregation notes of Lipocine's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.